The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Receives Approval for Japan’s 1st Propecia Generic
February 23, 2015
- Bristol-Myers Files Eliquis for Venous Thromboembolism
February 20, 2015
- AnGes MG Changes Collategene Sales Partner in Japan from Daiichi Sankyo to Mitsubishi Tanabe
February 19, 2015
- Daiichi Sankyo Restores Lixiana Supply via Shipping Adjustment Following Demand Surge
February 19, 2015
- Daiwa Securities Unit Sets Up Venture Capital Fund to Support Drug Development
February 19, 2015
- Edoxaban Can Cover 80% of NOAC-Targeted Patients despite Restricted Use: US Commercial Chief
February 18, 2015
- Ono, Dako to Jointly Develop Companion Diagnostic Test for Opdivo
February 18, 2015
- MSD, Sanofi to Copromote RotaTeq, Heptavax in Japan
February 18, 2015
- Takeda to Terminate Asian PIII Study for Motesanib
February 18, 2015
- Nichi-Iko to Exclusively Market Plavix Authorized Generics
February 17, 2015
- Lenvatinib Obtains World’s 1st Approval in US: Eisai
February 17, 2015
- Banzel Approved in US for Pediatric Use: Eisai
February 17, 2015
- Otsuka Holdings Weighs Staff Realignment as Abilify Patent Expiry Looms
February 16, 2015
- Merck Serono to Independently Promote Erbitux from May
February 16, 2015
- Otsuka Holdings Promotes Vice Chairman Ichiro Otsuka to Chairman on March 27
February 16, 2015
- Meiji Seika Pharma Completes Acquisition of Outstanding Shares of Medreich
February 16, 2015
- Antithrombotic Agent Sales Up 7.4% in 2014 on Buoyant Plavix, Xarelto: IMS
February 13, 2015
- GSK Eyes Transfer of Oncology Teams to Novartis from March
February 13, 2015
- Japan Pharma Market Grows 1.4% in 2014, Plavix Retains Crown in Sales Ranking: IMS
February 13, 2015
- AbbVie Files NDA for Chronic Hepatitis C Treatment in Japan
February 13, 2015
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…